MegaPro Biomedical Co (ROCO:6827) Net Margin %: 0.00% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6827 MegaPro Biomedical Co Ltd ROCO:6827
33 GF Score
Price NT$10.70
View Full Analysis

What is MegaPro Biomedical Co Net Margin %?

MegaPro Biomedical Co ROCO:6827 -2.28% 33 Net Margin % is 0.00% as of Dec. 2025. GuruFocus rates ROCO:6827 with a GF Score™ of 33/100. Among 941 Biotechnology companies, MegaPro Biomedical Co ranks worse than 106269.82% on this metric.

Net margin is calculated as Net Income divided by its Revenue. MegaPro Biomedical Co's Net Income for the six months ended in Dec. 2025 was NT$-52.17 Mil. MegaPro Biomedical Co's Revenue for the six months ended in Dec. 2025 was NT$0.00 Mil. Therefore, MegaPro Biomedical Co's net margin for the quarter that ended in Dec. 2025 was 0.00%.

The historical rank and industry rank for MegaPro Biomedical Co's Net Margin % or its related term are showing as below:


ROCO:6827's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -88.29
* Ranked among companies with meaningful Net Margin % only.

MegaPro Biomedical Co  (ROCO:6827) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

MegaPro Biomedical Co Net Margin % Related Terms

MegaPro Biomedical Co Net Margin % Historical Data

* Premium members only.

The historical data trend for MegaPro Biomedical Co's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MegaPro Biomedical Co Net Margin % Chart

MegaPro Biomedical Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial 0.00 0.00 -708,600.00 -1,171,721.43 0.00

MegaPro Biomedical Co Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -361,511.11 -551,671.43 0.00 0.00 0.00

ROCO:6827 vs VRTX, REGN, ALNY: Net Margin % Comparison

For the Biotechnology subindustry, MegaPro Biomedical Co's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MegaPro Biomedical Co Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MegaPro Biomedical Co's Net Margin % distribution charts can be found below:

* The bar in red indicates where MegaPro Biomedical Co's Net Margin % falls into.


ROCO:6827
33GF Score
MegaPro Biomedical Co Ltd ROCO:6827
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MegaPro Biomedical Co Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

MegaPro Biomedical Co's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-119.102/0
= %

MegaPro Biomedical Co's Net Margin for the quarter that ended in Dec. 2025 is calculated as

Net Margin=Net Income (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-52.166/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
MegaPro Biomedical Co (ROCO:6827) has a Net Margin % of 0.00% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on MegaPro Biomedical Co and its competitors. According to the industry distribution chart, MegaPro Biomedical Co ranks #999999 out of 941 companies in the Biotechnology industry.
Is MegaPro Biomedical Co's Net Margin % too high?
MegaPro Biomedical Co's current Net Margin % is 0.00%. Based on the distribution chart, MegaPro Biomedical Co ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MegaPro Biomedical Co has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does MegaPro Biomedical Co's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, MegaPro Biomedical Co ranks #999999 out of 941 companies for Net Margin %. This places MegaPro Biomedical Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on MegaPro Biomedical Co and its competitors. MegaPro Biomedical Co's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MegaPro Biomedical Co stock overvalued right now?
MegaPro Biomedical Co (ROCO:6827) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. MegaPro Biomedical Co's overall GF Score™ is 33/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For MegaPro Biomedical Co (ROCO:6827), the current Net Margin % is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MegaPro Biomedical Co Business Description

Address No. 66, Shengyi 5th Road, 10F-1, Hsinchu Science Park, Hsinchu, TWN, 31040
MegaPro Biomedical Co Ltd is a nanomedicine development company. The Company's only reportable operating segment is the Drug Application Development segment, which is engaged in the development of nano-iron oxide IOP drugs.
33GF Score

Get the complete analysis for ROCO:6827

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$10.70
Price